Ap Biosciences Inc.

Trican Biotechnology Co., Ltd.

Allgenesis Biotherapeutics Inc.

Innovent Biologics, Inc.

Innovent Biologis, Inc.

Huang-Tsu Chen

Jiun-Shyang Leou

Jeng-Horng Her

Li-Tsen Lin

Chung-Yuan Hsu

Cheng-Ke Li

Yun-Ting Wang

Ching-Hsuan Hsu

Pei-Tzu Wu

Kevin Zen

Shiou-Ting Chen

Chen-Wei Chiang

The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.

Anti-angiogenesis fusion protein and uses thereof

The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.

Protein inhibitors to complement and VEGF pathways and methods of use thereof

The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.

Human anti-CD47 antibodies and uses thereof

Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.

Fusion protein comprising a ligand binding domain of VEGF and PDGF

Growing community of inventors

Cupertino, CA, United States of America

Huang-Tsu Chen